Breaking News, Financial News

Financial Report: Hospira 3Q

Hospira

3Q Revenues: $925.5 million (+10%)

3Q Earnings: $81.8 million (+38%)

YTD Revenues: $2.7 billion (+9%)

YTD Earnings: $216.3 million (earnings were $60.7 million YTD07)

Comments: Revenue growth in the quarter was driven by strong sales in Specialty Injectable Pharmaceuticals as well as increased demand in Medication Management Systems product lines. Sales increased in all segments: the Americas (+10%); Europe (+10%), Middle East and Africa (EMEA) (+23%). YTD07 earnings reflect Mayne Pharma integration and other acquisition-related charges.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters